Navigation Links
EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models

ROCKVILLE, Md., June 01, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical results for its Aurora kinase - angiogenesis inhibitor, ENMD-981693. The data were presented during oral and poster presentations by EntreMed scientists at the 2nd Protein Kinases in Drug Discovery Conference being held May 31 - June 1, 2007 in Boston, Massachusetts.

ENMD-981693 is an oral, dual-acting kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. In preclinical studies, ENMD-981693 has been shown to inhibit a unique profile of angiogenic tyrosine kinase targets in addition to the Aurora kinases. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-981693 is selective for the Aurora A isoform in comparison to Aurora B.

Results from in vitro studies demonstrate ENMD-981693's potent activity against oncogenic receptor tyrosine kinases, including FLT3, c-Kit and CSF1R, which are involved in the pathology of hematological cancers. Additionally, ENMD-981693 demonstrated potent inhibition of a spectrum of targets linked to angiogenesis, including KDR (VEGFR2) and FGFR1. The compound was also shown to induce apoptosis and cell cycle arrest in a broad range of cell lines.

ENMD-981693 exhibited antiangiogenic activity in in vivo animal models by preventing the formation of new blood vessels and inducing regression of formed vessels at well-tolerated doses. Orally-administered ENMD-981693 induced tumor regression with minimal toxicity in a preclinical xenograft model of human leukemia. This activity is consistent with tumor regression induced by ENMD-981693 in preclinical models of human tumors derived from colon, leukemia, and breast cancer cell lines.

Mark
'"/>




Page: 1 2 3

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
5. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
6. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
7. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
Post Your Comments:
(Date:7/28/2015)... At the 2015 ICX Association Excellence ... 15 winners in the categories of digital signage, ... vertical markets. ContextMedia:Health proudly took home the ... success with its first-to-market Patient Education Exam ... leading provider of digital solutions at point-of-care, ...
(Date:7/28/2015)... 2015 Transparency Market Research (TMR) has ... Cancer Diagnostics Market - Global Industry Analysis, Size, Share, ... According to this report, the global cancer diagnostics market is ... forecast period of 2014 to 2020. In 2013, the global ... expected to be worth US$168,649.3 million by 2020.The increasing prevalence ...
(Date:7/28/2015)... Mike Rowe , spokesperson and reality television ... Pharmacy,s 2015 ThoughtSpot conference and tradeshow, which ... Las Vegas, Nev. Best known ... and Discovery Channel,s, "Dirty Jobs," Mr. Rowe spent a decade ... – people whose hard work, sacrifice and value aren,t always ...
Breaking Medicine Technology:ContextMedia:Health Receives Top Award at the ICX Association Excellence Awards 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 3Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 4Mike Rowe to Address Community Pharmacists at ThoughtSpot 2015 2
... diagnosisTAMPA, Fla., May 14 Moffitt Cancer ... have signed a license agreement on phospholipid ... been granted exclusive worldwide rights to Moffitt,s interests in ... maintenance fees, and royalties on sales. Moffitt and Frantz ...
... indicate statistically significant improvement in ACR20 responses over ... MEDX ) today announced that the ... active rheumatoid arthritis (RA) receiving methotrexate successfully met ... recently completed 70-patient multi-center, randomized, double-blind, placebo-controlled Phase ...
Cached Medicine Technology:Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC 2Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 2Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 3Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis 4
(Date:7/29/2015)... ... ... Hernia repairs have always been common and routine surgical procedures and technologies ... Center for Health Statistics indicates that more than five million Americans currently suffer from ... only effective treatment for a hernia is surgery, only about 750,000 Americans will actually ...
(Date:7/29/2015)... ... July 29, 2015 , ... Nature’s Artisan, a new holistic oral ... flavors. , Nature’s Artisan was founded by Tina Yarandi, who came up with the ... School of Dentistry. Tina was amazed when she learned about the incredible dental benefits ...
(Date:7/28/2015)... NY (PRWEB) , ... July 29, 2015 , ... ... honors Susan Bentley as a 2015-2016 inductee into its VIP Woman ... in healthcare. NAPW is the nation's leading networking organization exclusively for professional women, ...
(Date:7/28/2015)... ... ... The insurance telematics or usage-based insurance (UBI) industry has long called for the ... data and better understand customer behavior behind the wheel. , Up until recently, ... changing and automakers realize that with the Internet of Things, new modes of mobility ...
(Date:7/28/2015)... ... July 28, 2015 , ... The Memorial Cardiac and ... Hospital, providing expert, streamlined total advanced heart care for the South Florida community. ... services under one roof, including the treatment of advanced heart failure, adult heart ...
Breaking Medicine News(10 mins):Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 2Health News:National Statistics Reflect NCMA General Surgery Physicians Findings: Hernia Patients Who Seek Treatment Promptly are More Likely to Enjoy a Quick Recovery 3Health News:Discover a New Take on Oral Care with Nature’s Artisan Gourmet Mouthwashes 2Health News:National Association of Professional Women Inducts Susan Bentley, Owner of Women's Wellness Options, Into its VIP Woman of the Year Circle 2Health News:General Motors Engaging Insurance Partners for the Connected Car 2Health News:General Motors Engaging Insurance Partners for the Connected Car 3Health News:Memorial Cardiac And Vascular Institute Centralizes Cardiac Care Through It's New "Total Heart Center" At Memorial Regional Hospital 2
... Reporter , SUNDAY, Sept. 25 (HealthDay News) -- The bone ... risk of breast cancer recurrence, should not be used routinely ... new study of breast cancer patients, Zometa (zoledronic acid) did ... the risk of a serious side effect, said study co-author ...
... related fractures are an increasingly important health issue in the ... is currently over 50 years of age, in several countries ... and to 40% in 2050. Unless prevention strategies are put ... disability caused by fractures, particularly of the hip and spine. ...
... asthma who are admitted to hospital with pandemic influenza ... or require intensive care than those without asthma, according ... presented today (26 September 2011) at the European Respiratory ... being among the commonest illnesses seen in patients admitted ...
... a phase III clinical trial have shown that ... women with advanced breast cancer resistant to hormonal ... European Multidisciplinary Cancer Congress [1] that women treated ... an improved progression-free survival of nearly seven months ...
... , SUNDAY, Sept. 25 (HealthDay News) -- Self-compassion can ... most difficult periods of their lives, researchers suggest. ... toward oneself, recognition of common humanity, and the ability ... and positive outcomes in the face of divorce." ...
... Sweden: A trial investigating the use of zoledronic acid ... significant benefit for post-menopausal women, according to results presented ... (Sunday). Researchers think it could be the key for ... recurrence as well as offering new options for patient ...
Cached Medicine News:Health News:Bone Drug Fails to Prevent Breast Cancer Recurrence: Study 2Health News:Bone Drug Fails to Prevent Breast Cancer Recurrence: Study 3Health News:Bone experts to present strategies for osteoporosis prevention and care in Dubai 2Health News:People hospitalized with asthma 'less likely to die from swine flu' 2Health News:New hope for advanced post-menopausal breast cancer patients resistant to hormonal therapy 2Health News:'Self-Compassion' Can Help Divorced People Heal 2Health News:Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women 2Health News:Zoledronic acid reduces the recurrence of breast cancer in post-menopausal women 3
LCD monitors....
Camera and light source in one compact "Plug-and-Play" device....
... CXDI-40C is a highly sensitive DR system. ... area and it is designed for most ... comes in multiple wall stand and table ... the CXDI-40C efficiently produces detailed patient images ...
... is a flexible, total solution. , ,Kojair Tech ... since 1983. A major part of our production ... from all the different areas of clean-air needs ... Tech Oy is a comprehensive supplier. We are ...
Medicine Products: